<DOC>
	<DOCNO>NCT02029274</DOCNO>
	<brief_summary>This study investigate dose response relationship efficacy safety BAF312 compare placebo active DM patient treatment period 6+6 month determine minimum dose require maximal clinical effect . The study compose 2 period : double-blind period I BAF312 administered different daily dos ( 0.5 , 2 , 10 mg placebo ) fixed-dose Period II BAF312 administer dose 2 mg daily .</brief_summary>
	<brief_title>Safety Efficacy BAF312 Dermatomyositis</brief_title>
	<detailed_description />
	<mesh_term>Dermatomyositis</mesh_term>
	<criteria>Written informed consent must obtain assessment perform . Patients define `` definite '' `` probable '' base criterion Bohan Peter ( Bohan Peter 1975 ) dermatomyositis least 3 month screen Patients must active disease define muscle weakness Patients may stable dose corticosteroid ( up/equal 20 mg daily prednisone equivalent ) Patients currently treat oral subcutaneous MTX must stable dose more/equal 25 mg per week Patients currently treat Azathioprine must stable maintenance dose more/equal 3 mg/kg/day Negative cancer screen conduct 12 month prior screen visit Exclusion Criteria Dermatomyositis patient overlap myositis type myositis include paraneoplastic myositis , druginduced myopathy , necrotizing myositis Preexisting severe cardiac pulmonary condition , malignancy organ system significant eye disease . Uncontrolled diabetes mellitus diabetes complicate organ involvement . Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Dermatomyositis</keyword>
</DOC>